PSAT1 and lung carcinoma: In addition, human KRAS‐mutant lung cancer cell lines harboring NF1 mutations (i.e., H2030 and H2347) showed marked sensitivity to glutaminase and PSAT1 inhibition, while those with WT NF1 (i.e., H23, H2009, and H1792) displayed less sensitivity (Fig 4E).